At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Subscribe To Our Newsletter & Stay Updated
